anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Small bowel obstruction is a common general surgical diagnosis providing a significant proportion (16%) of the emergency general surgery admissions. Unfortunately, there is a paucity of clear, well defined management protocols for this very common problem which results in a wide array of management techniques used by the general surgeon. It has already been shown that CT scan with IV contrast is the most accurate method of identifying strangulated bowel, a diagnosis that requires urgent surgical intervention(4). There is no variability in this aspect of the treatment arm for ASBO, rather the variability is found in the medical management of ASBO. Nasogastric tube (NGT) decompression is a universal component of non-operative management but the duration of NGT therapy and the definition of failed medical management requiring surgery lack a clear consensus. It is this aspect of the management of ASBO that I am hoping to better define. Water soluble contrast (MD-Gastroview) has been shown to be both diagnostic and therapeutic in the management of ASBO decreasing length of stay in this patient population. Not only does it expedite the resolution of ASBO, but is also yields objective evidence whether or not ASBO will resolve with medical management alone, therefore decreasing delay in the inevitable surgical intervention.

The hypothesis of this study is that the implementation of an evidence based adhesive small bowel obstruction protocol can reduce length of stay and reduce the financial burden on the health care system regarding this common general surgical problem. A second hypothesis is that MD-Gastroview and omnipaque will have similar properties regarding their diagnostic and therapeutic impact on ASBO.
The use of an immunomodulator selected from the group consisting of (i) EtxB, CtxB or VtxB free from whole toxin; (ii) an agent other than EtxB or CtxB, having GM1-binding activity or an agent other than VtxB having Gb3-binding activity and (iii) an agent having effect on intracellular signaling events mediated by GM1-binding or Gb3 binding, in the preparation of a vaccine for treating one or more infectious diseases wherein if the vaccine also comprises an antigen or antigenic determinant the immunomodulator and antigen or antigenic determinant are separate moieties. Preferably the infectious disease is one for which the infectious agent is HSV-1, HSV-2, EBV, VZV, CMZ, HHV-6, HHV-7, HHV-8, influenza virus, parainfluenza virus, respiratory syncytial virus, hepatitis virus, meningitis, Streptococcus pneumonia, Legonella pneumophilia, mycobacterium tuberculosis, Neisseria meningitides, Haemophilus influenzae type B, Neisseria gonnorheae, HIV-1, HIV-2, chlamydia trachomatis, E. coli, rotavirus, Salmonella enteritidis, Salmonella typhi, Helicobacter pylori, Bacillus cereus, Campylobacter jejuni, Vibrio cholerae, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus mutans, malaria, Trypanasom spp. Toxoplasma gondii, Leishmania donovani or Oncocerca spp. Also described is the use of at least one antigenic determinant and an immunomodulator, as described above, in the manufacture of a medicament for the prevention or treatment of a disease, to upregulate the production of antibodies at mucosal surfaces, to prolong antigen presentation and give sustained immunological memory, for use against an infectious diseases and for prolonging presentation of the antigenic determinant and giving sustained immunological memory. The immunomodulator in conjugate with the antigen or antigenic determinant can be used in the preparation of a medicament for targeting the delivery of the antigen to the cytosol or nucleus of an antigen presenting cell or upregulating the presentation of the antigenic determinant derived form the antigen by MHC class I molecules. A vaccine composition comprises EtxB, CtxB or agent other than EtxB or CtB which has GM1-binding activity and an EBV antigen.
The invention discloses concentrated feed for small tailed han sheep. The concentrated feed comprises feed carriers and feed additives, wherein the feed carriers comprise wheat, common salt, corn grit, bone powder, peas, rice bran and bean seed meal; and the feed additives comprise enzyme compositions and traditional Chinese medicine additives. The enzyme compositions comprise xylanase, beta-dextranase, beta-mannase, cellulase, amylase, phytase and protease. The traditional Chinese medicine additives comprise angelica dahurica, selinum japenious seed, dried orange peel, pipewort, rhubarb, common selfheal fruit-spike, baical skullcap root, indigowoad leaf, codonopsis pilosula, Chinese angelica, medical stones, dahurian patrinia herb, charred triplet, uncaria and weeping forsythia. By the preparation method provided by the invention, brand new traditional Chinese medicine feed additives are added, so the concentrated feed has the advantages of effectively improving production performance of animals, along with low toxic and side effects, no drug resistance and the like, and residue is avoided; and the concentrated feed can effectively improve marketable fattened stock and quality of flesh. The additives contain nutritional substances such as rich amino acid, mineral substances and vitamins, benefit the supply of amino acid, mineral substances and vitamins which are short in the feed, and improve the utilization efficiency of the feed.
A real time, point-of-care and home phenylalanine monitoring system would provide patients with quick results and feedback. Home monitoring devices' phenylalanine measurements will be compared to the current gold-standard measurement of phenylalanine (plasma concentration) in four subjects with PKU and one control subject. The study will enroll subjects with different baseline phenylalanine concentrations (i.e., patients with poor to good metabolic control, assessed by comparing current phenylalanine concentrations to established treatment ranges).

For each prototype device, three separate measurements of phenylalanine per subject will be performed. Three prototype devices require whole blood, thus 1 teaspoon (approximately 4mL) of whole blood will be collected through venipuncture and blood spots will be used to conduct tests. One prototype requires capillary blood to be collected through a fingerstick, and will require three blood spots from the stick. A single plasma amino acid analysis for each participant will also be performed using leftover whole blood from the 4mL blood draw through quantitative ion exchange chromatography, reported as micromoles/L.
BACKGROUND: Robotic retro-muscular mesh repair of parastomal hernia (PH) is possible with transversus abdominis release. The aim of this study is to report mid-term results with this method.
METHODS: Patients who underwent surgery for PH were enrolled in a prospective study. Patients with concomitant midline hernia also underwent Rives repair. Polypropylene meshes with an absorbable buffer mesh were used in the retro-muscular pocket-except PTFE was chosen for inflammatory bowel disease patients. Follow-up was by telephone and physical examination and CT if suspicion of complication.
RESULTS: Of the 56 included ostomy patients, 44 had colostomies, 10 had ileostomies, and two had urostomies. Thirty-nine percent had a concomitant hernia, and 25% had recurrent PH. The mean operating time without accessory repair was 156 min (SD 37), and with accessory repairs 220 min (SD 62). One bowel lesion and one vascular injury to the stoma occurred, prompting intraoperative stoma revision without postoperative morbidity. Postoperative complications ensued in 12 patients (23%). One patient had stoma necrosis after 3 weeks and the stoma was relocated. One patient had a mesh infection, 3 patients temporary ileus, one patient hypovolemic renal failure, and two patients experienced a flare-up of their Crohn's Disease. One parastomal abscess was drained percutaneously. The median postoperative stay was 3 days (1-21; mean 3.7 days), and the readmission rate was 8.9%. The recurrence rate at mean and median 24 months follow-up is 5.4%, two in ileostomy patients and one colostomy patient with unaltered bulging where CT shows a relatively large prolapse and recorded as a failure.
CONCLUSION: Robotic Pauli repair has shown promising results. However, repair fails of PH at small bowel ostomies with short mesentery. ePauli/TAR is now the preliminary choice for eligible patients at our site. Comparative studies with the intraperitoneal mesh standard are needed.
Hypersensitivity to bromocriptine or to any of the excipients of Parlodel (bromocriptine mesylate), uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia, Parlodel should be withdrawn when pregnancy is diagnosed (see PRECAUTIONS, Hyperprolactinemic States). In the event that Parlodel is reinstituted to control a rapidly expanding macroadenoma (see PRECAUTIONS, Hyperprolactinemic States) and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing Parlodel must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. When Parlodel is being used to treat acromegaly, prolactinoma, or Parkinson’s disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of Parlodel is considered to be medically contraindicated.

The drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the postpartum period, the patient should be observed with caution.
GH001 is administered via inhalation, as an IDR consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience \[PE\]) at the previously administered dose.
Autism Spectrum Disorder (ASD) and Developmental Language Disorder (DLD) have traditionally been considered separate disorders, although some similarities and overlaps in certain aspects of language have been detected. In this paper, we compare the deficits in receptive grammar in these two disorders. We analyse the proportion of grammatical errors in relation to semantic complexity in 84 children divided into four groups: children with autism language impairment (ALI), with autism language normal (ALN), with DLD, and with typical development (TD), all groups with the same age of receptive vocabulary. The results show significant differences in the comprehension of grammatical structures, both simple (canonical and non-reversible) and complex (non-canonical and reversible). Children with ASD and DLD show different language profiles depending on the syntactic complexity. In the simplest structures, no differences are found between the groups, starting at an equivalent vocabulary age of 7:8 years. However, there are differences between the ALI and DLD groups with respect to the TD group in the more complex structures, starting at an equivalent vocabulary age of 3 years. Therefore, both groups ALI and DLD present the greatest difficulties compared to ALN and TD. The paper discusses the importance of attending to these differences, since the repercussion of comprehension difficulties increases as children grow.
Chronic inflammatory and immune responses play key roles in the development and progression of chronic obstructive pulmonary disease (COPD). PANoptosis, as a unique inflammatory cell death modality, is involved in the pathogenesis of many inflammatory diseases. We aim to identify critical PANoptosis-related biomarkers and explore their potential effects on respiratory tract diseases and immune infiltration landscapes in COPD. Total microarray data consisting of peripheral blood and lung tissue datasets associated with COPD were obtained from the GEO database. PANoptosis-associated genes in COPD were identified by intersecting differentially expressed genes (DEGs) with genes involved in pyroptosis, apoptosis, and necroptosis after normalizing and removing the batch effect. Furthermore, GO, KEGG, PPI network, WGCNA, LASSO-COX, and ROC curves analysis were conducted to screen and verify hub genes, and the correlation between PYCARD and infiltrated immune cells was analyzed. The effect of PYCARD on respiratory tract diseases and the potential small-molecule agents for the treatment of COPD were identified. PYCARD expression was verified in the lung tissue of CS/LPS-induced COPD mice. PYCARD was a critical PANoptosis-related gene in all COPD patients. PYCARD was positively related to NOD-like receptor signaling pathway and promoted immune cell infiltration. Moreover, PYCARD was significantly activated in COPD mice mainly by targeting PANoptosis. PANoptosis-related gene PYCARD is a potential biomarker for COPD diagnosis and treatment.
Residents in the intervention arm will receive (in addition to the core foundation course) 6 email modules and practice video communication assessments on weight management counseling. They will also attend 2 educational session and take part in all 3 assessments (including 3 surveys and 2 video communication assessments) over the course of 18 months.
The present invention concerns a human hexose kinase 13 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes a human hexose kinase 13.
The invention relates to a medicine used for treating decompensated liver cirrhosis, and a preparation method thereof. Currently, decompensated liver cirrhosis is treated by liver protection, human plasma albumin and diuretic intravenous supplement, repeated ascites paracentesis, and the like. The treatment course is long, and treatment effect is poor. The medicine provided by the invention comprises: Mongolian milkvetch root, largehead atractylodes rhizome, swordlike atractylodes rhizome, agaric, florist's chrysanthemum, Asiatic plantain seed, common yam rhizome, ginseng, stir-fried malt, stir-fried medicated leaven, salvia miltiorrhiza, radix saussureae, hawthorn fruit, dandelion, mix-fried scale, mix-fried turtle shell, peach seed, rhubarb, composite protein powder, lecithin vitamin E, and colostrum capsules. The medicine provided by the invention is used for treating decompensated liver cirrhosis diseases. The medicine has the functions of hard mass softening, stasis removing, spleen invigorating, and dampness removing. Through liver protection, dieresis, and nutritional immunology effect improving, ascite is discharged. The medicine has a good treatment effect against decompensated liver cirrhosis after alcoholic hepatitis or viral hepatitis.
First 15-days period with daily intake of 1.5l of tap water. 15-days washout period Last 15-days period with daily intake of 1.5l of sodium bicarbonate-rich mineral water.
Dismemberment and subsequent burning are common methods employed in an attempt to conceal or destroy evidence. While kerf characteristics can be utilised to identify tool(s) used for dismemberment, further research is necessary to assess the effect of burning on these characteristics. In this study, a back (tenon) saw (13 teeth per inch) was used to manually inflict trauma on Ovis aries de-fleshed femur bones (n = 18). Three different cut marks (shallow false start, incomplete cut and complete transection) were made on the mid-shaft of each bone. Subsequently, the bones were burned for 20 minutes in a muffle furnace. Three burn temperatures were assessed: 400 °C, 600 °C and 800 °C. Saw mark characteristics of each cut type were assessed and compared pre- and post-burning. All pre-existing trauma was recognisable post-burning; however, metric and morphological alterations were apparent. An increase in kerf width was observed at 600 °C in false start lesions and 800 °C in incomplete cuts. Breakaway spur thickness decreased post-burning (at 400 °C and 800 °C) but length was not significantly affected. Mean inter-striation distance decreased post burning at all temperature groups. Saw marks were distinguishable from heat-related fractures across all temperature groups. One false start lesion was obliterated at 800 °C. Exit chipping, pull-out striae as well as striation regularity appeared to be more enhanced after heat exposure. These alterations indicate a temperature-dependent impact on these characteristics. Further research is necessary to assess the role of burn duration.
Minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage. The study of DNA damage induced by UV will be done by immunohistochemical analysis of markers validated in previous studies: CPD=pyridine dimers, 6.4 PP= "6.4 photoproducts", and p53. Immunolabeling will be performed on skin biopsies collected 15 minutes after UV exposure and 48 hours after UV exposure.
This invention relates to medicine compositions of foaming tablet agent, suspending agent or powder agent types that are capable of exterminating helicobacter pylori and its fabrication method. The medicine compositions of foaming tablet agent type, suspending agent type or powder agent type include an effective dose of β-lactams antibiotic, an effective dose of macrolides antibiotic, and an effective dose of antacid such as proton pump inhibitor (PPI), and an medically acceptable carrier such as excipient, flavor enhancer, foaming agent, glidant, antibacterial agent, suspending agent, disintegrant, and lubricant, etc. The suspending agent type medicine composition is obtained by firstly mixing β-lactams antibiotic and disintegrant, and added with the mixture of macrolides antibiotic and suspending agent, then added with antacid, and finally uniformly mixing with the medically acceptable carrier that contains lubricant. The powder agent type medicine composition is obtained by mixing antacid and suspending agent, and added with the mixture of macrolides antibiotic and a medically acceptable carrier, then added with β-lactams antibiotic, and finally uniformly mixing with the medically acceptable carrier that contains lubricant. The foaming agent type medicine composition is obtained by firstly mixing antacid and a medically acceptable carrier that contains foaming agent, then added with β-lactams antibiotic and macrolides antibiotic, and then subjected to particle-making and tablet-pressing processes. The medicine compositions of foaming agent type and powder agent type use an alkali substance to increase the pH of gastric acid so that the antacid and antibiotic will not be degraded easily in stomach and have an increased stability in stomach, beneficial to stomach working functions and increasing the bioavailability of the medicine in human body.
A total of 1058 patients with type 2 diabetes mellitus participated in a 24-week, randomized, double-blind, placebo-controlled study designed to assess the efficacy of linagliptin in combination with a sulfonylurea and metformin. The most common sulfonylureas used by patients in the study were glimepiride (31%), glibenclamide (26%), and gliclazide (26% [not available in the United States]). Patients on a sulfonylurea and metformin were randomized to receive linagliptin 5 mg or placebo, each administered once daily. Patients who failed to meet specific glycemic goals during the study were treated with pioglitazone rescue. Glycemic end points measured included A1C and FPG.

In combination with a sulfonylurea and metformin, linagliptin provided statistically significant improvements in A1C and FPG compared with placebo (Table 10). In the entire study population (patients on linagliptin in combination with a sulfonylurea and metformin), a mean reduction from baseline relative to placebo in A1C of -0.6% and in FPG of -13 mg/dL was seen. Rescue therapy was used in 5.4% of patients treated with linagliptin 5 mg and in 13% of patients treated with placebo. Change from baseline in body weight did not differ significantly between the groups.
Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3

The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
A wound therapy system includes a negative pressure circuit, a pump, a pressure sensor, and a controller. The negative pressure circuit applies negative pressure to a wound. The pump is fluidly coupled to the negative pressure circuit and produces a negative pressure at the wound or within the negative pressure circuit. The pressure sensor measures the negative pressure within the negative pressure circuit or the wound. The controller performs a testing procedure including a first drawdown period, a leak rate determination period, a vent period, and a second drawdown period. The controller is configured to receive one or more pressure measurements of the pressure sensor over the leak rate determination period to determine a leak rate parameter, monitor an amount of elapsed time over the second drawdown period to determine a drawdown parameter, and estimate a volume of the wound based on the leak rate parameter and the drawdown parameter.